These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 9713514)

  • 1. Reduction of susceptibility to NK lysis in cisplatin-resistant K562 cell lines.
    Dedoussis G; Menounos P; Papadopoulos N; Gounaris A; Karameris A
    Anticancer Res; 1998; 18(4C):3081-5. PubMed ID: 9713514
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human tumor cell line resistance to chemotherapeutic agents does not predict resistance to natural killer or lymphokine-activated killer cell-mediated cytolysis.
    Harker WG; Tom C; McGregor JR; Slade L; Samlowski WE
    Cancer Res; 1990 Sep; 50(18):5931-6. PubMed ID: 1975512
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antileukemia activity of a natural killer cell line against human leukemias.
    Yan Y; Steinherz P; Klingemann HG; Dennig D; Childs BH; McGuirk J; O'Reilly RJ
    Clin Cancer Res; 1998 Nov; 4(11):2859-68. PubMed ID: 9829753
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glutathione depletion restores the susceptibility of cisplatin-resistant chronic myelogenous leukemia cell lines to Natural Killer cell-mediated cell death via necrosis rather than apoptosis.
    Dedoussis GV; Andrikopoulos NK
    Eur J Cell Biol; 2001 Sep; 80(9):608-14. PubMed ID: 11675936
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cisplatin treatment renders tumor cells more susceptible to attack by lymphokine-activated killer cells.
    Yamaue H; Tanimura H; Noguchi K; Iwahashi M; Tsunoda T; Tani M; Tamai M; Hotta T; Mizobata S; Arii K
    J Clin Lab Immunol; 1991 Aug; 35(4):165-70. PubMed ID: 1668852
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The interaction of human natural killers with target cells of the K562 line and its sublines characterized by multiple drug resistance and thermoresistance].
    Davtian TK; Blinova GI; Ignatova TN; Aleksanian IuT; Meliksetian MB
    Biull Eksp Biol Med; 1993 Dec; 116(12):616-8. PubMed ID: 8123821
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhanced susceptibility of cis-diamminedichloroplatinum-treated K562 cells to lysis by peripheral blood lymphocytes and lymphokine activated killer cells.
    Mizutani Y; Bonavida B; Nio Y; Yoshida O
    Cancer; 1993 Feb; 71(4):1313-21. PubMed ID: 7679609
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Altered IFNgamma signaling and preserved susceptibility to activated natural killer cell-mediated lysis of BCR/ABL targets.
    Cebo C; Voutsadakis IA; Da Rocha S; Bourhis JH; Jalil A; Azzarone B; Turhan AG; Chelbi-Alix M; Chouaib S; Caignard A
    Cancer Res; 2005 Apr; 65(7):2914-20. PubMed ID: 15805294
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhancement of natural killer cytotoxicity by cis-diamminedichloroplatinum (II) in vivo and in vitro.
    Lichtenstein AK; Pende D
    Cancer Res; 1986 Feb; 46(2):639-44. PubMed ID: 3940633
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Natural killer resistance of a drug-resistant leukemia cell line, mediated by up-regulation of HLA class I expression.
    Classen CF; Falk CS; Friesen C; Fulda S; Herr I; Debatin KM
    Haematologica; 2003 May; 88(5):509-21. PubMed ID: 12745270
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Resistance to natural killer cell-mediated cytolysis by a pleiotropic drug-resistant human erythroleukemia (K562-R) cell line.
    Yanovich S; Hall RE; Weinert C
    Cancer Res; 1986 Sep; 46(9):4511-5. PubMed ID: 2425955
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of an oxidation-resistant tumor cell line and its sensitivity to immune response and chemotherapy.
    Sauri H; Kim AT; Shau H
    J Surg Res; 1995 May; 58(5):526-35. PubMed ID: 7745966
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relation of natural killer cell line NK-92-mediated cytolysis (NK-92-lysis) with the surface markers of major histocompatibility complex class I antigens, adhesion molecules, and Fas of target cells.
    Komatsu F; Kajiwara M
    Oncol Res; 1998; 10(10):483-9. PubMed ID: 10338151
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oxaliplatin induces drug resistance more rapidly than cisplatin in H69 small cell lung cancer cells.
    Stordal BK; Davey MW; Davey RA
    Cancer Chemother Pharmacol; 2006 Aug; 58(2):256-65. PubMed ID: 16283310
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oxaliplatin in treatment of the cisplatin-resistant MKN45 cell line of gastric cancer.
    Tozawa K; Oshima T; Kobayashi T; Yamamoto N; Hayashi C; Matsumoto T; Miwa H
    Anticancer Res; 2008; 28(4B):2087-92. PubMed ID: 18751380
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Endogenous interleukin 6 conveys resistance to cis-diamminedichloroplatinum-mediated apoptosis of the K562 human leukemic cell line.
    Dedoussis GV; Mouzaki A; Theodoropoulou M; Menounos P; Kyrtsonis MC; Karameris A; Maniatis A
    Exp Cell Res; 1999 Jun; 249(2):269-78. PubMed ID: 10366426
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunosensitization of resistant human tumor cells to cytotoxicity by tumor infiltrating lymphocytes.
    Frost P; Caliliw R; Belldegrun A; Bonavida B
    Int J Oncol; 2003 Feb; 22(2):431-7. PubMed ID: 12527945
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trophoblast cell line resistance to NK lysis mainly involves an HLA class I-independent mechanism.
    Avril T; Jarousseau AC; Watier H; Boucraut J; Le Bouteiller P; Bardos P; Thibault G
    J Immunol; 1999 May; 162(10):5902-9. PubMed ID: 10229826
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination chemotherapy of paclitaxel and cisplatin induces apoptosis with Bcl-2 phosphorylation in a cisplatin-resistant human epidermoid carcinoma cell line.
    Sawada S; Mese H; Sasaki A; Yoshioka N; Matsumura T
    Cancer Chemother Pharmacol; 2003 Jun; 51(6):505-11. PubMed ID: 12709826
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased expression of thioredoxin/adult T-cell leukemia-derived factor in cisplatin-resistant human cancer cell lines.
    Yamada M; Tomida A; Yoshikawa H; Taketani Y; Tsuruo T
    Clin Cancer Res; 1996 Feb; 2(2):427-32. PubMed ID: 9816187
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.